CUTANEOUS T-CELL LYMPHOMA

This study tests whether the drug ruxolitinib can help prevent T-cell lymphoma from returning and reduce graft-versus-host disease (GVHD) after a stem cell transplant. About 44 adults with T-cell lymphoma who are in remission after transplant will take ruxolitinib as a maintenanc…

This study tests a combination of two drugs, pembrolizumab and mogamulizumab, for people with advanced-stage cutaneous T-cell lymphoma (CTCL) that has come back or not responded to prior treatment. The goal is to see how many patients achieve a complete response (no detectable ca…

This early-phase study tests a combination of two drugs, mogamulizumab and brentuximab vedotin, in people with a rare type of skin lymphoma (CTCL or MF) that has been treated before. The main goal is to find a safe dose and see how well the combination is tolerated. About 10 adul…

This early-phase trial tests a new drug called ST-001 (a form of fenretinide) in people with T-cell non-Hodgkin lymphoma whose cancer has returned or not responded to prior treatments. The main goal is to find the safest dose and understand side effects. About 46 participants wil…

This study tests the safety of combining a vitamin A-like drug (bexarotene) with very low-dose radiation to the whole skin for people with a type of skin lymphoma called mycosis fungoides. The goal is to see if giving both treatments together works better than either alone. About…

This study tests whether a blood-filtering treatment called photopheresis can improve early-stage cutaneous T-cell lymphoma (a type of skin cancer). About 74 adults with stage IA to IIA disease will receive the therapy, which is currently used only for advanced stages. The goal i…

This study tests a cream called tofacitinib for people with early-stage cutaneous T-cell lymphoma (CTCL), a type of skin cancer. The goal is to see if the cream is safe and can help control the disease. About 20 adults with stage IA, IB, or IIA CTCL will apply the cream and be mo…

This early-phase trial tests an investigational drug called ropeginterferon in 38 adults with cutaneous T-cell lymphoma (CTCL), a rare type of skin cancer. The study aims to find the safest dose and see if the drug can shrink tumors. Participants must have tried at least two othe…

This early-phase trial tests whether a patient's own immune cells, modified in a lab to recognize and attack a protein called CCR4 on cancer cells, can safely treat certain T-cell lymphomas that have not responded to standard therapy. About 60 adults with relapsed or refractory p…

This study tests a drug called golidocitnib in people with certain slow-growing but incurable blood cancers (T/NK-cell lymphomas) that have not responded to standard treatment. About 48 adults will receive the drug to see if it shrinks tumors and how safe it is. The goal is to co…

This study tests a gel called HyBryte that, when activated by light, targets cancer cells in the skin. It is for people with early-stage cutaneous T-cell lymphoma (a rare type of skin lymphoma). About 80 participants will apply the gel to their skin lesions and then receive a spe…

This study collects blood, urine, and skin samples from 200 adults with cutaneous T-cell lymphoma, eczema, or atopic dermatitis. The samples are stored for current and future research to better understand these conditions. Participants must be 18 or older and have a confirmed dia…

This study collects information from medical records of 400 adults with cutaneous T-cell lymphoma to see which systemic (body-wide) treatments doctors actually use and in what order. It aims to describe real-world treatment patterns, not to test a new drug. Participants must have…

This study looks at the types of bacteria living on the skin of people with cutaneous T cell lymphoma and compares them to bacteria on healthy people of similar age and sex. Researchers aim to understand if differences in skin bacteria are linked to the disease. About 300 partici…